Abstract Leucocalocybe mongolica (S. Imai) is a well-known edible medicinal mushroom. Polysaccharides extracted from L. mongolica show several pharmacological properties. Owing to increased predation and desertification, wild L. mongolica populations are declining and becoming increasingly rare. Microbial fermentation is emerging as a suitable alternative to obtain bioactive compounds from this mushroom. In this study, polysaccharides were isolated from the solid-state fermentation of L. mongolica (LMPs) and their anti-tumor activities were investigated. Treatment with LMPs significantly inhibited the growth of hepatoma H22 tumors after cell transplantation in mice. Notably, LMP treatment protected the spleen and the thymus against tumor-induced damage. Furthermore, LMP administration significantly increased the serum levels of the cytokines interferon gamma, tumor necrosis factor-α, interleukin (IL)-6 and IL-2, while simultaneously decreasing the serum level of vascular endothelial growth factor. Hematoxylin-eosin staining, the TUNEL assay, immunohistochemistry and western blotting indicated that the in vivo anti-tumor activity of LMP was achieved by promoting apoptosis and inhibiting angiogenesis. In summary, this study revealed that LMPs markedly suppressed the tumor growth of H22-transplanted tumors in vivo at least partly by enhancing the immune response, inducing apoptosis and inhibiting angiogenesis. These findings highlight LMP as a potential low-cost anti-tumor drug.

中文翻译：

---

使用固态发酵从蒙古白菜多糖中获得的多糖的抗肿瘤活性

摘要 Leucocalocybe mongolica (S. Imai) 是一种著名的药用食用菌。从 L. mongolica 中提取的多糖显示出多种药理特性。由于捕食和荒漠化的加剧，野生蒙古蜂种群正在下降并变得越来越稀有。微生物发酵正在成为从这种蘑菇中获取生物活性化合物的合适替代方法。在这项研究中，多糖是从蒙古包 (LMPs) 的固态发酵中分离出来的，并研究了它们的抗肿瘤活性。LMPs 治疗显着抑制了小鼠细胞移植后肝癌 H22 肿瘤的生长。值得注意的是，LMP 治疗保护脾脏和胸腺免受肿瘤诱导的损伤。此外，LMP 给药显着增加了细胞因子干扰素 γ、肿瘤坏死因子-α、白细胞介素 (IL)-6 和 IL-2 的血清水平，同时降低了血管内皮生长因子的血清水平。苏木精-伊红染色、TUNEL 检测、免疫组化和蛋白质印迹表明 LMP 的体内抗肿瘤活性是通过促进细胞凋亡和抑制血管生成来实现的。总之，该研究表明，LMPs 至少部分通过增强免疫反应、诱导细胞凋亡和抑制血管生成显着抑制体内 H22 移植肿瘤的肿瘤生长。这些发现突出了 LMP 作为一种潜在的低成本抗肿瘤药物。同时降低血清血管内皮生长因子水平。苏木精-伊红染色、TUNEL 检测、免疫组化和蛋白质印迹表明 LMP 的体内抗肿瘤活性是通过促进细胞凋亡和抑制血管生成来实现的。总之，该研究表明，LMPs 至少部分通过增强免疫反应、诱导细胞凋亡和抑制血管生成显着抑制体内 H22 移植肿瘤的肿瘤生长。这些发现突出了 LMP 作为一种潜在的低成本抗肿瘤药物。同时降低血清血管内皮生长因子水平。苏木精-伊红染色、TUNEL 检测、免疫组化和蛋白质印迹表明 LMP 的体内抗肿瘤活性是通过促进细胞凋亡和抑制血管生成来实现的。总之，该研究表明，LMPs 至少部分通过增强免疫反应、诱导细胞凋亡和抑制血管生成显着抑制体内 H22 移植肿瘤的肿瘤生长。这些发现突出了 LMP 作为一种潜在的低成本抗肿瘤药物。该研究表明，LMPs 至少部分通过增强免疫反应、诱导细胞凋亡和抑制血管生成显着抑制体内 H22 移植肿瘤的肿瘤生长。这些发现突出了 LMP 作为一种潜在的低成本抗肿瘤药物。该研究表明，LMPs 至少部分通过增强免疫反应、诱导细胞凋亡和抑制血管生成显着抑制体内 H22 移植肿瘤的肿瘤生长。这些发现突出了 LMP 作为一种潜在的低成本抗肿瘤药物。